Showing 3891-3900 of 9394 results for "".
- Ipsen's Dysport Approved for Use in Canadahttps://practicaldermatology.com/news/20130418-ipsens_dysport_approved_for_use_in_canada/2459560/Health Canada granted a marketing authorization for Dysport (Botulinum toxin type A for injection) for the temporary improvement in the appearance of moderate to severe frown lines (glabellar lines) in adult patients younger than 65 years of age. Medicis Aesthetics Canada, a division of Valeant Phar
- Review: GLP-1 Receptor Agonists May Benefit Both Psoriasis and Metabolic Diseasehttps://practicaldermatology.com/news/review-glp-1-receptor-agonists-may-benefit-both-psoriasis-and-metabolic-disease/2487389/Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may offer additional benefits for patients with psoriasis, according to a new review and primer from the National Psoriasis Foundation Medical Board. The authors noted GLP-1 RAs have been associated with reductions in Psoriasis Area and
- SCRATCH-AD: Rapid Itch Reduction, Biomarker Improvements with Ruxolitinibhttps://practicaldermatology.com/news/scratch-ad-rapid-itch-reduction-biomarker-improvements-with-ruxolitinib/2487381/Patients with atopic dermatitis (AD) treated with ruxolitinib 1.5% cream experienced rapid and sustained reductions in itch alongside improvements in disease-associated biomarkers, according to findings from the SCRATCH-AD study presented in the June 2026 issue of the Journal of Investigative Der
- Avapritinib Shows Dermatologic Benefits in Indolent Systemic Mastocytosishttps://practicaldermatology.com/news/avapritinib-shows-dermatologic-benefits-in-indolent-systemic-mastocytosis/2487380/Treatment with avapritinib led to substantial improvements in cutaneous disease manifestations among patients with indolent systemic mastocytosis (ISM), according to results from the phase 2 PIONEER study. Investigators for
- Study: Mineral Sunscreen Whitening Linked to Reduced Application and Protectionhttps://practicaldermatology.com/news/study-links-mineral-sunscreen-whitening-to-reduced-application-and-protection/2487379/New research published in the Journal of Drugs in Dermatology indicates mineral sunscreens produced visible whitening across all skin tones, with a pronounced effect in darker skin tones. Investigators evaluated 5 mi
- Study: AI Model Outperforms Early-Career Physicians in Skin Lesion Diagnosishttps://practicaldermatology.com/news/analysis-ai-model-outperforms-early-career-physicians-in-skin-lesion-diagnosis/2487332/Data from a new study show that a foundational AI model outperformed early career dermatologists in skin lesion diagnosis, but not more experienced dermatologists, when using a dataset designed to reflect real-world clinical scenarios.
- Genital Psoriasis Consensus Offers Age-Specific Roadmap for Clinical Carehttps://practicaldermatology.com/news/genital-psoriasis-consensus-offers-age-specific-roadmap-for-clinical-care/2487330/A new expert consensus manuscript in the American Journal of Clinical Dermatology offered recommendations aimed at improving the diagnosis and management of genital psoriasis, according to a press release from Arcutis. The publication represents the second manuscript, Arcutis said
- Skin Cancer Champions Announces Patient Advocacy Summithttps://practicaldermatology.com/news/skin-cancer-champions-announces-patient-advocacy-summit/2487322/The inaugural Patient Advocacy Summit, hosted by Skin Cancer Champions, will be held on October 30, 2026, at The Fairmont Copley Plaza in Boston, Massachusetts, the organization announced. “The Summit is an important milestone in our mission of providing support, advocacy, and amplifying t
- Analysis: Capecitabine Shows Clinical Activity in Advanced Head and Neck Cutaneous SCChttps://practicaldermatology.com/news/neoadjuvant-capecitabine-yields-42-complete-pathologic-response-rate-in-advanced-cscchn/2487303/Neoadjuvant capecitabine demonstrated encouraging clinical and pathologic responses in patients with advanced cutaneous squamous cell carcinoma of the head and neck (cSCCHN), according to findings from a prosp
- Rubedo Reports Early Clinical Activity for GPX4 Modulator RLS-1496 in Actinic Keratosishttps://practicaldermatology.com/news/rubedo-reports-early-clinical-activity-for-gpx4-modulator-rls-1496-in-actinic-keratosis/2487263/Rubedo Life Sciences announced preliminary findings from a Phase 1b/2a trial evaluating topical RLS-1496 1% cream in adults with actinic keratosis (AK), reporting reductions in lesion counts alongside favorable tolerability data. The interim findings were presented at the RBC Capital Markets Glob